AUTHORS
Eric Matthew Jurgens, MD, Andriy Derkach, PhD2, Tasmin Farzana, MPH3, Natalie Solberg, MPH4, Kylee Maclachlan, MD, PhD5, Malin Hultcrantz, MD PhD6, Hani Hassoun, MD7, Sham Mailankody, MBBS8, Urvi A. Shah, MD, MS, DipABLM9, Sridevi Rajeeve, MD10, Hamza Hashmi, M.D.11, Ross Firestone, MD/PhD12, Maximilian Merz, MD13, Francesco Maura, MD14, Gunjan L. Shah, MD, MS15, Michael Scordo, MD16, Heather J. Landau, MD17, Sergio Giralt, MD18, Neha Korde, MD19, Alexander M. Lesokhin, MD20, Saad Z. Usmani, MD21, Carlyn Rose Tan, MD22
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Introduction
In multiple myeloma (MM), t(11;14) is a common, standard risk cytogenetic abnormality. While t(11;14) confers therapeutic sensitivity to BCL-2 inhibitors, the impact on response to BCMA-targeted T cell redirection therapies (TCRT), bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T cell therapy, is unclear. Herein, we present outcomes of patients with t(11;14) treated with BCMA-targeted TCRTs.
Methods
To determine the prognostic significance of t(11;14) in response to BCMA-targeted TCRTs we performed a single center retrospective review of all patients with relapsed/refractory MM (RRMM) treated with standard of care BCMA-targeted BsAbs (teclistamab, elranatamab, or linvoseltamab) or CAR T cell therapy (ciltacabtagene autoleucel; cilta-cel) between July 21, 2022 and February 27, 2026. Presence of t(11;14) as well as high risk (HR) cytogenetics t(4;14), t(14;16), t(14;20), or del(17p) were determined via standard FISH testing on pre-treatment bone marrow and/or plasmacytoma biopsies. Treatment response rate (RR), depth (≥very good partial response [VGPR]), progression free survival (PFS), and overall survival (OS) were compared according to t(11;14) status.
Results
In total, we identified 398 patients treated with BCMA-targeted TCRT including 183 treated with BsAbs and 215 with CAR T cell therapy. T(11;14) was detected in 25 (18%) and 37 (17%) patients treated with BsAbs and CAR T cell therapy respectively. Baseline characteristics including age, sex, prior lines of therapy, HR cytogenetics, and extramedullary disease (EMD) were similar according to t(11;14) status.
Amongst the entire BCMA-targeted TCRT cohort, patients with vs without t(11;14) did not demonstrate significant differences in RR (73% vs 79%, p=0.3) or depth (≥VGPR; 66% vs 69%, p=0.6). Similarly, t(11;14) was not associated with inferior PFS (Hazard Ratio [HR] 1.18; 95% confidence interval [CI] 0.80-1.76) or OS (HR 1.11; 95% CI 0.68-1.81). HR cytogenetics were, however, associated with inferior PFS (HR 2.01; 95% CI 1.42-2.84) and OS (HR 2.49; 95% CI 1.58-3.90).
Regarding individual therapeutic modalities, BsAb treatment in patients with vs without t(11;14) exhibited similar RR (50% vs 52%, p=0.8), depth (≥VGPR; 42% vs 43%, p=0.9), PFS (HR 0.72; 95% CI 0.41-1.27) and OS (HR 0.86; 95% CI 0.45-1.62). Additionally, CAR T cell therapy in patients with vs without t(11;14) demonstrated similar RR (95% vs 95%, p=0.4), depth (≥VGPR; 89% vs 85%, p=0.5), PFS (HR 1.56; 95% CI 0.90-2.73) and OS (HR 1.72; 95% CI 0.81-3.64).
Conclusion
The presence of t(11;14) did not appear to impact treatment response, PFS, or OS following BCMA-targeted TCRT for RRMM. Expectedly, the presence of HR cytogenetics was associated with inferior outcomes. Finally, t(11;14) did not associate with worse outcomes for either individual modality, BsAbs or CAR T cell therapy.
DISCLOSURES
Eric Matthew Jurgens, MD: Johnson and Johnson - Consultancy (Includes expert testimony)